ArticleFrontiers in microbiology2026
Gut microbiota alters cardiac metabolism and immune system composition in viral myocarditis mice.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effects of the gut microbiota on the regulation of host physiology have recently garnered considerable attention, particularly in metabolism and the immune system. However, the role of the gut microbiota in viral myocarditis (VMC) remains to be fully elucidated. Methods: Balb/c mice were injected with CVB3 to induce VMC. VMC mice were treated with fecal microbiota transplantation (FMT) or antibiotics (ABX) to evaluate the therapeutic effects of these interventions. Echocardiography, HE, and Masson's staining of the heart were used to assess cardiac function and pathological changes. 16S rDNA sequencing was conducted to explore alterations in gut microbial composition. UPLC-MS/MS-based metabolomics was used to detect disturbances of cardiac metabolic profiles. Flow cytometry was applied to analyze the dynamics of immune cell subsets, including M1, M2, Th1, Th2, Th17, and Treg cells. RT-PCR was performed to quantify cytokine expression levels in the heart. Results: FMT reduced cardiac inflammation and fibrosis, enhanced heart function, remodeled the structure of gut microbiota in VMC, and increased bacterial diversity, with an enrichment of p-Proteobacteria, the reduction of g-Pseudomonas, g-Streptococcus, and g-Ralstonia. Meanwhile, FMT induced alterations in cardiac metabolites in VMC, with enrichment of the steroid hormone biosynthesis pathway. A significant negative correlation was found between desoxycortone, corticosterone, 21-deoxycortisol, and cortodoxone with p_Spirochaetota and p_Kapabacteria. Furthermore, FMT reduced the proportions of M1 macrophages, Th1, and Th17 cells, as well as the cytokines TNF-a, IL-6, and IL-1β, and increased M2 macrophages and Treg cells. Regarding the role of antibiotics in VMC, our findings indicated that antibiotics altered the gut microbiota, myocardial metabolism, and immune response. Compared with antibiotics, FMT exerted a better effect on the alleviation of cardiac inflammation and fibrosis. Conclusion: In VMC mice, the gut microbiota, which mediates disturbances in cardiac metabolites and the host immune response, may contribute significantly to the development of cardiac inflammation and fibrosis. Furthermore, FMT may represent a promising therapeutic approach for VMC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.